Serum YKL-40 predicts long-term mortality in patients with stable coronary disease: a prognostic study within the CLARICOR trial

Research output: Contribution to journal › Journal article › peer-review

Standard

Serum YKL-40 predicts long-term mortality in patients with stable coronary disease : a prognostic study within the CLARICOR trial. / Harutyunyan, Marina; Gøtze, Jens P; Winkel, Per; Johansen, Julia S; Hansen, Jørgen Fischer; Jensen, Gorm Boje; Hilden, Jørgen; Kjøller, Erik; Kolmos, Hans J; Gluud, Christian; Kastrup, Jens.

In: Immunobiology, Vol. 218, No. 7, 07.2013, p. 945-51.

Research output: Contribution to journal › Journal article › peer-review

Harvard

Harutyunyan, M, Gøtze, JP, Winkel, P, Johansen, JS, Hansen, JF, Jensen, GB, Hilden, J, Kjøller, E, Kolmos, HJ, Gluud, C & Kastrup, J 2013, 'Serum YKL-40 predicts long-term mortality in patients with stable coronary disease: a prognostic study within the CLARICOR trial', Immunobiology, vol. 218, no. 7, pp. 945-51. https://doi.org/10.1016/j.imbio.2012.10.015

APA

Harutyunyan, M., Gøtze, J. P., Winkel, P., Johansen, J. S., Hansen, J. F., Jensen, G. B., Hilden, J., Kjøller, E., Kolmos, H. J., Gluud, C., & Kastrup, J. (2013). Serum YKL-40 predicts long-term mortality in patients with stable coronary disease: a prognostic study within the CLARICOR trial. Immunobiology, 218(7), 945-51. https://doi.org/10.1016/j.imbio.2012.10.015

Vancouver

Harutyunyan M, Gøtze JP, Winkel P, Johansen JS, Hansen JF, Jensen GB et al. Serum YKL-40 predicts long-term mortality in patients with stable coronary disease: a prognostic study within the CLARICOR trial. Immunobiology. 2013 Jul;218(7):945-51. https://doi.org/10.1016/j.imbio.2012.10.015

Author

Harutyunyan, Marina ; Gøtze, Jens P ; Winkel, Per ; Johansen, Julia S ; Hansen, Jørgen Fischer ; Jensen, Gorm Boje ; Hilden, Jørgen ; Kjøller, Erik ; Kolmos, Hans J ; Gluud, Christian ; Kastrup, Jens. / Serum YKL-40 predicts long-term mortality in patients with stable coronary disease : a prognostic study within the CLARICOR trial. In: Immunobiology. 2013 ; Vol. 218, No. 7. pp. 945-51.

Bibtex

@article{4759787c5d4c48ba967f8c25afa908fb,
title = "Serum YKL-40 predicts long-term mortality in patients with stable coronary disease: a prognostic study within the CLARICOR trial",
abstract = "OBJECTIVE: We investigated whether the inflammatory biomarker YKL-40 could improve the long-term prediction of death made by common risk factors plus high-sensitivity C-reactive protein (hs-CRP) and N-terminal-pro-B natriuretic peptide (NT-proBNP) in patients with stable coronary artery disease (CAD).BACKGROUND: Non-hospitalized CAD patients are usually followed in general practice. There is a need for identify biomarkers which could help to foresee the prognoses of these patients. Elevated serum YKL-40 is a short-term predictor for myocardial infarction, cardiovascular mortality and all-cause mortality in patients with stable CAD.METHODS: Serum YKL-40, hs-CRP, and NT-proBNP were measured in 4265 (97.6%) of the 4372 patients with stable CAD included in the CLARICOR trial, and death was registered in a 6-years follow-up period.RESULTS: The median serum YKL-40 was 110 μg/L [IQR=93], hs-CRP 2.8 mg/L [IQR=4.74], and NT-proBNP 203 ng/L [IQR=407]. During 6 years follow-up period 923 (21.1%) patients died. After adjustment for type of intervention, risk factors (age, sex, hypertension, diabetes, smoking status, and previous myocardial infarction) and medical treatment (diuretics, digoxin, and statin) serum YKL-40 (transformed as ln(max(82, YKL-40/μg/L)) was significantly associated with all-cause mortality [hazard ratio (HR)=1.55, 95% CI=1.39-1.73, p<0.001]. After additional adjustment for ln(hs-CRP) and ln(NT-proBNP) this was still true [HR=1.38, 95% CI=1.21-1.53, p<0.001].CONCLUSIONS: Serum YKL-40 is a predictor of long-term mortality in patients with stable CAD independent of common risk factors and ln(hs-CRP) and ln(NT-proBNP). Serum YKL-40 can be used for prognostication in these patients.",
keywords = "Adipokines, Aged, Biological Markers, C-Reactive Protein, Cardiotonic Agents, Case-Control Studies, Coronary Artery Disease, Female, Follow-Up Studies, Humans, Lectins, Male, Middle Aged, Natriuretic Peptide, Brain, Peptide Fragments, Predictive Value of Tests, Prognosis, Risk Factors, Survival Analysis",
author = "Marina Harutyunyan and G{\o}tze, {Jens P} and Per Winkel and Johansen, {Julia S} and Hansen, {J{\o}rgen Fischer} and Jensen, {Gorm Boje} and J{\o}rgen Hilden and Erik Kj{\o}ller and Kolmos, {Hans J} and Christian Gluud and Jens Kastrup",
note = "Copyright {\textcopyright} 2012 Elsevier GmbH. All rights reserved.",
year = "2013",
month = jul,
doi = "10.1016/j.imbio.2012.10.015",
language = "English",
volume = "218",
pages = "945--51",
journal = "Immunobiology",
issn = "0171-2985",
publisher = "Urban und Fischer Verlag",
number = "7",

}

RIS

TY - JOUR

T1 - Serum YKL-40 predicts long-term mortality in patients with stable coronary disease

T2 - a prognostic study within the CLARICOR trial

AU - Harutyunyan, Marina

AU - Gøtze, Jens P

AU - Winkel, Per

AU - Johansen, Julia S

AU - Hansen, Jørgen Fischer

AU - Jensen, Gorm Boje

AU - Hilden, Jørgen

AU - Kjøller, Erik

AU - Kolmos, Hans J

AU - Gluud, Christian

AU - Kastrup, Jens

N1 - Copyright © 2012 Elsevier GmbH. All rights reserved.

PY - 2013/7

Y1 - 2013/7

N2 - OBJECTIVE: We investigated whether the inflammatory biomarker YKL-40 could improve the long-term prediction of death made by common risk factors plus high-sensitivity C-reactive protein (hs-CRP) and N-terminal-pro-B natriuretic peptide (NT-proBNP) in patients with stable coronary artery disease (CAD).BACKGROUND: Non-hospitalized CAD patients are usually followed in general practice. There is a need for identify biomarkers which could help to foresee the prognoses of these patients. Elevated serum YKL-40 is a short-term predictor for myocardial infarction, cardiovascular mortality and all-cause mortality in patients with stable CAD.METHODS: Serum YKL-40, hs-CRP, and NT-proBNP were measured in 4265 (97.6%) of the 4372 patients with stable CAD included in the CLARICOR trial, and death was registered in a 6-years follow-up period.RESULTS: The median serum YKL-40 was 110 μg/L [IQR=93], hs-CRP 2.8 mg/L [IQR=4.74], and NT-proBNP 203 ng/L [IQR=407]. During 6 years follow-up period 923 (21.1%) patients died. After adjustment for type of intervention, risk factors (age, sex, hypertension, diabetes, smoking status, and previous myocardial infarction) and medical treatment (diuretics, digoxin, and statin) serum YKL-40 (transformed as ln(max(82, YKL-40/μg/L)) was significantly associated with all-cause mortality [hazard ratio (HR)=1.55, 95% CI=1.39-1.73, p<0.001]. After additional adjustment for ln(hs-CRP) and ln(NT-proBNP) this was still true [HR=1.38, 95% CI=1.21-1.53, p<0.001].CONCLUSIONS: Serum YKL-40 is a predictor of long-term mortality in patients with stable CAD independent of common risk factors and ln(hs-CRP) and ln(NT-proBNP). Serum YKL-40 can be used for prognostication in these patients.

AB - OBJECTIVE: We investigated whether the inflammatory biomarker YKL-40 could improve the long-term prediction of death made by common risk factors plus high-sensitivity C-reactive protein (hs-CRP) and N-terminal-pro-B natriuretic peptide (NT-proBNP) in patients with stable coronary artery disease (CAD).BACKGROUND: Non-hospitalized CAD patients are usually followed in general practice. There is a need for identify biomarkers which could help to foresee the prognoses of these patients. Elevated serum YKL-40 is a short-term predictor for myocardial infarction, cardiovascular mortality and all-cause mortality in patients with stable CAD.METHODS: Serum YKL-40, hs-CRP, and NT-proBNP were measured in 4265 (97.6%) of the 4372 patients with stable CAD included in the CLARICOR trial, and death was registered in a 6-years follow-up period.RESULTS: The median serum YKL-40 was 110 μg/L [IQR=93], hs-CRP 2.8 mg/L [IQR=4.74], and NT-proBNP 203 ng/L [IQR=407]. During 6 years follow-up period 923 (21.1%) patients died. After adjustment for type of intervention, risk factors (age, sex, hypertension, diabetes, smoking status, and previous myocardial infarction) and medical treatment (diuretics, digoxin, and statin) serum YKL-40 (transformed as ln(max(82, YKL-40/μg/L)) was significantly associated with all-cause mortality [hazard ratio (HR)=1.55, 95% CI=1.39-1.73, p<0.001]. After additional adjustment for ln(hs-CRP) and ln(NT-proBNP) this was still true [HR=1.38, 95% CI=1.21-1.53, p<0.001].CONCLUSIONS: Serum YKL-40 is a predictor of long-term mortality in patients with stable CAD independent of common risk factors and ln(hs-CRP) and ln(NT-proBNP). Serum YKL-40 can be used for prognostication in these patients.

KW - Adipokines

KW - Aged

KW - Biological Markers

KW - C-Reactive Protein

KW - Cardiotonic Agents

KW - Case-Control Studies

KW - Coronary Artery Disease

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Lectins

KW - Male

KW - Middle Aged

KW - Natriuretic Peptide, Brain

KW - Peptide Fragments

KW - Predictive Value of Tests

KW - Prognosis

KW - Risk Factors

KW - Survival Analysis

U2 - 10.1016/j.imbio.2012.10.015

DO - 10.1016/j.imbio.2012.10.015

M3 - Journal article

C2 - 23294528

VL - 218

SP - 945

EP - 951

JO - Immunobiology

JF - Immunobiology

SN - 0171-2985

IS - 7

ER -

ID: 135270768